CRMD250117P18000
- 0.00
- 0.000.00%
CorMedix Newsroom
CorMedix Inc. (NASDAQ:CRMD) On The Verge Of Breaking Even
D. Boral Capital Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $15
Cormedix Analyst Ratings
D. Boral Capital Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $15
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix (CRMD) Receives a Buy From Truist Financial
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Cormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth Prospects
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Sector Update: Health Care Stocks Mixed Premarket Tuesday
CorMedix Shares Advance After Reporting Preliminary Q4 Net Revenue
CorMedix | 8-K: CorMedix Inc. announces preliminary Fourth quarter 2024 results and provides business update
Express News | CorMedix Inc - Prelim, FY 2025 Operating Expense Guidance of $72-$78 Mln, Excluding Non-Cash & One-Time Items
Express News | CorMedix Inc - Has $25 Mln in Exisiting Open Purchase Orders for Q1 2025
CorMedix Sees 4Q Rev $31M >CRMD
Press Release: CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
Express News | CorMedix Q4 Cash & Investments USD 52 Million
CORMEDIX INC. ANNOUNCES PRELIMINARY FOURTH QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE